




10 FY2008 (Fiscal Year Ending March 31, 2009) Financial Results Presentation





Safe Harbor Statement

. .

- Materials and information provided during this presentation may contain socalled "forward-looking statements." These statements are based on current expectations, forecasts and assumptions that are subject to risks and uncertainties which could cause actual outcomes and results to differ materially from these statements.
- Risks and uncertainties include general industry and market conditions, and general domestic and international economic conditions such as interest rate and currency exchange fluctuations. Risks and uncertainties particularly apply with respect to product-related forward-looking statements. Product risks and uncertainties include, but are not limited to, technological advances and patents attained by competitors; challenges inherent in new product development, including completion of clinical trials; claims and concerns about product safety and efficacy; obtaining regulatory approvals; domestic and foreign healthcare reforms; trends toward managed care and healthcare cost containment; and governmental laws and regulations affecting domestic and foreign operations.
- Also, for products that are approved, there are manufacturing and marketing risks and uncertainties, which include, but are not limited to, inability to build production capacity to meet demand, unavailability of raw materials, and failure to gain market acceptance.
- The Company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.



1Q Consolidated Performance

. .

(billions of yen, %)

	1Q FY2007		1Q FY2008				
	Results	%	Results (Adjusted*)	%	YOY		Results (GAAP)
Net Sales	176.0	100.0	195.8	100.0	111	-	195.8
Cost of Sales	27.5	15.6	33.8	17.3	123	5.6	39.4
Gross Profits	148.5	84.4	162.0	82.7	109		156.5
R&D Expenses	30.5	17.3	35.5	18.1	116	0.2	35.7
SG&A Expenses	91.8	52.2	94.4	48.2	103	2.3	96.7
Operating Income	26.2	14.9	32.1	16.4	123		24.1
Ordinary Income	28.4	16.1	31.9	16.3	113		23.9
Net Income	19.3	11.0	22.6	11.6	117		16.6



Sales to Customers by Geographical Area (billion of yen, %)

	1Q FY2007		1Q FY2008				
	Results	%	Results	%	YOY	Increase (Decrease)	
Japan	78.3	44.5	84.5	43.1	108	6.2	
North America	76.8	43.6	89.5	45.7	117	12.7	
\$ Million	636		856		135	221	
Europe	14.1	8.0	13.9	7.1	99	(0.1)	
China	2.3	1.3	2.8	1.4	122	0.5	
Asia and others	4.6	2.6	5.1	2.6	110	0.5	
Overseas	97.8	55.5	111.3	56.9	114	13.6	
Total	176.0	100.0	195.8	100.0	111	19.8	





	1Q FY2007					
	Results					
North America	4.1	14.0	8.3	24.8	201	4.2
China	0.5	1.8	0.6	1.9	119	



1Q Consolidated Cash Income

Cash Income =

. .

 Net Income/Loss + Amortization of Tangible/Intangible Assets + IPR&D (In-Process R&D) Expenses + Amortization of Goodwill + Impairment Loss

(billions of yen, %)

	1Q FY2007	1Q FY2008		
		Results	YOY	Increase (Decrease)
Net Income/Loss	19.3	16.6	86	(2.7)
Amortization of Tangible/Intangible Assets	7.3	12.3	169	5.0
In Process R&D Expenses	0.6	-	-	(0.6)
Amortization of Goodwill	0.0	2.3	-	2.3
Impairment Loss	-	0	-	00
Cash Income = a+b+c+d+e	27.3	31.2	115	4.0





		1Q FY2007		1Q FY2008			
		Results	%	Results (Adjusted)	%	YOY	Increase (Decrease)
Net Revenue		644	100.0	863	100.0	134	219
Aricept [®]		343	53.3	415	48.1	121	72
AcipHex®		263	40.9	248	28.7	94	(16)
Aricept [®] +	AcipHex®	607	94.2	663	76.8	109	56
	Aloxi®	-		90		-	90
	Dacogen®	-		42		-	42
a .	Gliadel [®] Wafer	-		11		-	11
Oncology	Others	-		4		-	4
	MGI Total	-		147		-	147
	ONTAK®	5		8		170	3
	Targretin [®]	5		10		181	4
	Lymphoma Products, etc. Total	10		18		174	8
	Fragmin [®]	12		22		187	10
	Total	22	3.4	187	21.7	850	165
Operating Income		29	4.6	80			







Aricept[®]: Ongoing Development to Enhance Value for Patients During and Beyond DLP

Pediatric Usage: two-pronged approach for underserved population

- Cognitive impairment due to Down Syndrome (Phase II ongoing, Phase III to be initiated)
- Cognitive impairment due to chemotherapy (Phase III to be initiated)
- Targeting data submission in U.S. in FY2009

Transdermal Patch: goal - g

. .

Sustained Release (SR): goal - enhanced efficacy

- Goal is to achieve superior efficacy with high-dose donepezil 23 mg
- Phase III study ongoing to compare SR to currently marketed 10mg
- Targeting NDA submission in U.S. in FY2009



Pariet[®]/AcipHex[®]: Ongoing Development to Enhance Value for Patients During and Beyond DLP

Patent validity and enforceability upheld

. .

 U.S. Federal Circuit Court of Appeals fully upheld Eisai's favorable ruling in AcipHex[®]'s patent infringement lawsuit against Teva and Dr. Reddy's (July 21, 2008)

Extended Release (ER): goal - long-acting 24-hour relief with superior efficacy in erosive GERD






Steady Progress of Major Projects



Steady Progress of Pipeline







Progress of 4 Corporate Programs


. .

		Phase I	Phase II	Phase III	Submission Target
	Neuropathic Pain				FY2010
	Epilepsy				FY2012
E5564	Severe Sepsis				FY2009
	Breast Cancer				FY2009
	Prostate Cancer, Non-Small Cell Lung Cancer, and Sarcoma				
Aricept	Pediatric Usage: Cognitive Impairment Due To Down Syndrome				FY2009
	Pediatric Usage: Cognitive Impairment Due To Chemotherapy				FY2009
	Sustained Release Formulation				FY2009
	Transdermal Patch Formulation				FY2009



Rising Area of Oncology -From Small Molecules to Biologics-

. .







Japan

- J Prescription pharmaceuticals sales increased by 12% YOY
- J Outperformed the market by 6 points* (IMS data)
- J Ranked No.1 in the growth rate among top 10 Japanese peers
- J Aricept[®] sales: +30% YOY
- J Pariet[®] sales: +23% YOY

J Started marketing of Stronger Neo-Minophagen[®] C on April 1

- J lomeron[®] 350 and lomeron[®] 350 syringe received additional approval for usage in dynamic computed tomography of the liver imaging (dynamic CT) on May 20
- J Launched Humira[®] Subcutaneous Injection 40mg Syringe 0.8mL on June 18; strong kick-off
- J Launched ethical drugs Bufferin 81mg Tablets and Bufferin 330mg on July 1
- J Restriction on long-term administration for once-weekly formulation of Actonel[®] lifted on July 1
- J Actonel[®] received approval for additional indication in patients with Paget's disease of bone on July 16

U.S.

- J Sales by prescription pharmaceuticals
- business increased by 34% YOY Operating income before royalty
- deduction increased by 44% YOY

Aricept[®] sales: +21% YOY AcipHex[®] sales: -6% YOY (as anticipated) China: Sales +28% YOY; Operatin